Search Results - "Sabari, K"

Fuzzy logic-based prediction and parametric optimizing using particle swarm optimization for performance improvement in pyramid solar still by Senthilkumar, N, Yuvaperiyasamy, M, Deepanraj, B, Sabari, K

“…The primary objective of this study is to develop a robust model that employs a fuzzy logic interface (FL) and particle swarm optimization (PSO) to forecast…”
Get full text

Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer by Suzawa, Ken, Offin, Michael, Lu, Daniel, Kurzatkowski, Christopher, Vojnic, Morana, Smith, Roger S, Sabari, Joshua K, Tai, Huichun, Mattar, Marissa, Khodos, Inna, de Stanchina, Elisa, Rudin, Charles M, Kris, Mark G, Arcila, Maria E, Lockwood, William W, Drilon, Alexander, Ladanyi, Marc, Somwar, Romel

“…exon 14 splice site alterations that cause exon skipping at the mRNA level ( ex14) are actionable oncogenic drivers amenable to therapy with MET tyrosine…”
Get full text

Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes by Chang, Jason C, Offin, Michael, Falcon, Christina, Brown, David, Houck-Loomis, Brian R, Meng, Fanli, Rudneva, Vasilisa A, Won, Helen H, Amir, Sharon, Montecalvo, Joseph, Desmeules, Patrice, Kadota, Kyuichi, Adusumilli, Prasad S, Rusch, Valerie W, Teed, Sarah, Sabari, Joshua K, Benayed, Ryma, Nafa, Khedoudja, Borsu, Laetitia, Li, Bob T, Schram, Alison M, Arcila, Maria E, Travis, William D, Ladanyi, Marc, Drilon, Alexander, Rekhtman, Natasha

“…Invasive mucinous adenocarcinoma (IMA) is a unique subtype of lung adenocarcinoma, characterized genomically by frequent mutations or specific gene fusions,…”
Get full text

Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study by Park, Keunchil, Haura, Eric B, Leighl, Natasha B, Mitchell, Paul, Shu, Catherine A, Girard, Nicolas, Viteri, Santiago, Han, Ji-Youn, Kim, Sang-We, Lee, Chee Khoon, Sabari, Joshua K, Spira, Alexander I, Yang, Tsung-Ying, Kim, Dong-Wan, Lee, Ki Hyeong, Sanborn, Rachel E, Trigo, José, Goto, Koichi, Lee, Jong-Seok, Yang, James Chih-Hsin, Govindan, Ramaswamy, Bauml, Joshua M, Garrido, Pilar, Krebs, Matthew G, Reckamp, Karen L, Xie, John, Curtin, Joshua C, Haddish-Berhane, Nahor, Roshak, Amy, Millington, Dawn, Lorenzini, Patricia, Thayu, Meena, Knoblauch, Roland E, Cho, Byoung Chul

“…Non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor ( ) exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved…”
Get full text

Changing the Therapeutic Landscape in Non-small Cell Lung Cancers: the Evolution of Comprehensive Molecular Profiling Improves Access to Therapy by Sabari, Joshua K., Santini, Fernando, Bergagnini, Isabella, Lai, W. Victoria, Arbour, Kathryn C., Drilon, Alexander

“…Targeting genomic alterations has led to a paradigm shift in the treatment of patients with lung cancer. In an effort to better identify potentially actionable…”
Get full text

A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers by Sabari, Joshua K, Offin, Michael, Stephens, Dennis, Ni, Andy, Lee, Adrian, Pavlakis, Nick, Clarke, Stephen, Diakos, Connie I, Datta, Sutirtha, Tandon, Nidhi, Martinez, Andres, Myers, Mackenzie L, Makhnin, Alex, Leger, Ysleni, Yu, Helena A, Paik, Paul K, Chaft, Jamie E, Kris, Mark G, Jeon, Jeong O, Borsu, Laetitia A, Ladanyi, Marc, Arcila, Maria E, Hernandez, Jennifer, Henderson, Samantha, Shaffer, Tristan, Garg, Kavita, DiPasquo, Dan, Raymond, Christopher K, Lim, Lee P, Li, Mark, Hellmann, Matthew D, Drilon, Alexander, Riely, Gregory J, Rusch, Valerie W, Jones, David R, Rimner, Andreas, Rudin, Charles M, Isbell, James M, Li, Bob T

“…Abstract Background Liquid biopsy for plasma circulating tumor DNA (ctDNA) next-generation sequencing (NGS) is commercially available and increasingly adopted…”
Get full text

Multiple synchronous primary lung adenocarcinomas with distinct epidermal growth factor receptor mutations: A case report by Siskin, Matthew, Sabari, Joshua K.

“…•We present the case of a woman with two synchronous primary lung adenocarcinomas each harboring unique EGFR mutations, one classical and the other rare.•Her…”
Get full text

Dynamic Management of Lung Cancer Care During Surging COVID-19 by Wang, Annie, Chang, Stephanie H, Kim, Eric J, Bessich, Jamie L, Sabari, Joshua K, Cooper, Benjamin, Geraci, Travis C, Cerfolio, Robert J

“…Management of patients with lung cancer continues to be challenging during the COVID-19 pandemic, due to the increased risk of complications in this subset of…”
Get full text

Next-generation sequencing based detection of germline and somatic alterations in a patient with four metachronous primary tumors by Martin, Madhuri, Sabari, Joshua K., Turashvili, Gulisa, Halpenny, Darragh F., Rizvi, Hira, Shapnik, Natalie, Makker, Vicky

“…Multiple primary tumors (MPTs) are defined as two or more separate synchronous or metachronous neoplasms occurring in different sites in the same individual…”
Get full text

Unravelling the biology of SCLC: implications for therapy by Sabari, Joshua K., Lok, Benjamin H., Laird, James H., Poirier, John T., Rudin, Charles M.

“…Key Points Small-cell lung cancer (SCLC) is a high-grade neuroendocrine tumour associated with a poor overall survival, and limited progress has been made in…”
Get full text

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer by Arbour, Kathryn C, Mezquita, Laura, Long, Niamh, Rizvi, Hira, Auclin, Edouard, Ni, Andy, Martínez-Bernal, Gala, Ferrara, Roberto, Lai, W Victoria, Hendriks, Lizza E L, Sabari, Joshua K, Caramella, Caroline, Plodkowski, Andrew J, Halpenny, Darragh, Chaft, Jamie E, Planchard, David, Riely, Gregory J, Besse, Benjamin, Hellmann, Matthew D

“…Treatment with programmed cell death-1 or programmed death ligand 1 (PD-(L)1) inhibitors is now standard therapy for patients with lung cancer. The…”
Get full text

Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation by Jänne, Pasi A., Riely, Gregory J., Gadgeel, Shirish M., Heist, Rebecca S., Ou, Sai-Hong I., Pacheco, Jose M., Johnson, Melissa L., Sabari, Joshua K., Leventakos, Konstantinos, Yau, Edwin, Bazhenova, Lyudmila, Negrao, Marcelo V., Pennell, Nathan A., Zhang, Jun, Anderes, Kenna, Der-Torossian, Hirak, Kheoh, Thian, Velastegui, Karen, Yan, Xiaohong, Christensen, James G., Chao, Richard C., Spira, Alexander I.

“…Adagrasib produced responses in 43% of previously treated patients with non–small-cell lung cancer containing a KRAS G12C mutation, with median overall…”
Get full text

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1) by Ou, Sai-Hong Ignatius, Jänne, Pasi A., Leal, Ticiana A., Rybkin, Igor I., Sabari, Joshua K., Barve, Minal A., Bazhenova, Lyudmila, Johnson, Melissa L., Velastegui, Karen L., Cilliers, Cornelius, Christensen, James G., Yan, Xiaohong, Chao, Richard C., Papadopoulos, Kyriakos P.

“…Adagrasib (MRTX849) is an oral, highly selective, small-molecule, covalent inhibitor of KRAS G12C . We report results from a phase I/IB study of adagrasib in…”
Get full text

Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation by Bekaii-Saab, Tanios S, Yaeger, Rona, Spira, Alexander I, Pelster, Meredith S, Sabari, Joshua K, Hafez, Navid, Barve, Minal, Velastegui, Karen, Yan, Xiaohong, Shetty, Aditya, Der-Torossian, Hirak, Pant, Shubham

“…Adagrasib, a KRASG12C inhibitor, has demonstrated clinical activity in patients with KRASG12C-mutated non-small-cell lung cancer (NSCLC) and colorectal cancer…”
Get full text

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions by Zhou, Caicun, Tang, Ke-Jing, Cho, Byoung Chul, Liu, Baogang, Paz-Ares, Luis, Cheng, Susanna, Kitazono, Satoru, Thiagarajan, Muthukkumaran, Goldman, Jonathan W, Sabari, Joshua K, Sanborn, Rachel E, Mansfield, Aaron S, Hung, Jen-Yu, Boyer, Michael, Popat, Sanjay, Mourão Dias, Josiane, Felip, Enriqueta, Majem, Margarita, Gumus, Mahmut, Kim, Sang-We, Ono, Akira, Xie, John, Bhattacharya, Archan, Agrawal, Trishala, Shreeve, S Martin, Knoblauch, Roland E, Park, Keunchil, Girard, Nicolas

“…Amivantamab has been approved for the treatment of patients with advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor ( ) exon 20…”
Get full text

Seeing Beyond the Smoke: Reclassifying Lung Cancer by Smoking-Related Mutational Signatures by Moreira, Andre L, Sabari, Joshua K

Get more information

Adagrasib in Non-Small-Cell Lung Cancer. Reply by Jänne, Pasi A, Sabari, Joshua K, Spira, Alexander I

Get full text

Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer by Sabari, Joshua K, Velcheti, Vamsidhar, Shimizu, Kazuhide, Strickland, Matthew R, Heist, Rebecca S, Singh, Mohini, Nayyar, Naema, Giobbie-Hurder, Anita, Digumarthy, Subba R, Gainor, Justin F, Rajan, Anant P, Nieblas-Bedolla, Edwin, Burns, Aaron C, Hallin, Jill, Olson, Peter, Christensen, James G, Kurz, Sylvia C, Brastianos, Priscilla K, Wakimoto, Hiroaki

“…Patients with KRAS-mutant non-small cell lung cancer (NSCLC) with brain metastases (BM) have a poor prognosis. Adagrasib (MRTX849), a potent oral…”
Get full text

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers by Sabari, J.K., Leonardi, G.C., Shu, C.A., Umeton, R., Montecalvo, J., Ni, A., Chen, R., Dienstag, J., Mrad, C., Bergagnini, I., Lai, W.V., Offin, M., Arbour, K.C., Plodkowski, A.J., Halpenny, D.F., Paik, P.K., Li, B.T., Riely, G.J., Kris, M.G., Rudin, C.M., Sholl, L.M., Nishino, M., Hellmann, M.D., Rekhtman, N., Awad, M.M., Drilon, A.

“…MET exon 14 alterations are actionable oncogenic drivers. Durable responses to MET inhibitors are observed in patients with advanced MET exon 14-altered lung…”
Get full text

Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRASG12C-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS Metastases by Negrao, Marcelo V, Spira, Alexander I, Heist, Rebecca S, Jänne, Pasi A, Pacheco, Jose M, Weiss, Jared, Gadgeel, Shirish M, Velastegui, Karen, Yang, Wenjing, Der-Torossian, Hirak, Christensen, James G, Sabari, Joshua K

“…Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be…”
Get full text